nodes	percent_of_prediction	percent_of_DWPC	metapath
Tramadol—CHRM3—nephrolithiasis	0.811	1	CbGaD
Tramadol—Coordination disturbance—Hydrochlorothiazide—nephrolithiasis	0.0153	0.0967	CcSEcCtD
Tramadol—CHRM3—ureter—nephrolithiasis	0.00974	0.461	CbGeAlD
Tramadol—Stress—Hydrochlorothiazide—nephrolithiasis	0.00877	0.0556	CcSEcCtD
Tramadol—Hair disorder—Hydrochlorothiazide—nephrolithiasis	0.00484	0.0307	CcSEcCtD
Tramadol—Abnormal faeces—Hydrochlorothiazide—nephrolithiasis	0.00385	0.0244	CcSEcCtD
Tramadol—Blood potassium increased—Hydrochlorothiazide—nephrolithiasis	0.00364	0.0231	CcSEcCtD
Tramadol—Cardiac murmur—Hydrochlorothiazide—nephrolithiasis	0.00355	0.0225	CcSEcCtD
Tramadol—Local swelling—Hydrochlorothiazide—nephrolithiasis	0.00315	0.0199	CcSEcCtD
Tramadol—Gastric irritation—Hydrochlorothiazide—nephrolithiasis	0.00284	0.018	CcSEcCtD
Tramadol—Joint swelling—Hydrochlorothiazide—nephrolithiasis	0.00224	0.0142	CcSEcCtD
Tramadol—Epigastric discomfort—Hydrochlorothiazide—nephrolithiasis	0.00209	0.0133	CcSEcCtD
Tramadol—Anorectal disorder—Hydrochlorothiazide—nephrolithiasis	0.00209	0.0133	CcSEcCtD
Tramadol—Sleep disturbance—Hydrochlorothiazide—nephrolithiasis	0.00196	0.0124	CcSEcCtD
Tramadol—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00196	0.0124	CcSEcCtD
Tramadol—Toothache—Hydrochlorothiazide—nephrolithiasis	0.00181	0.0115	CcSEcCtD
Tramadol—CYP3A4—urine—nephrolithiasis	0.00174	0.0824	CbGeAlD
Tramadol—Encephalopathy—Hydrochlorothiazide—nephrolithiasis	0.00171	0.0109	CcSEcCtD
Tramadol—CYP2D6—urine—nephrolithiasis	0.00171	0.0811	CbGeAlD
Tramadol—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.00163	0.0103	CcSEcCtD
Tramadol—Blood creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0016	0.0101	CcSEcCtD
Tramadol—OPRD1—renal system—nephrolithiasis	0.00153	0.0725	CbGeAlD
Tramadol—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.00153	0.00967	CcSEcCtD
Tramadol—OPRD1—kidney—nephrolithiasis	0.00148	0.0701	CbGeAlD
Tramadol—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.00144	0.0091	CcSEcCtD
Tramadol—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00888	CcSEcCtD
Tramadol—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00134	0.00847	CcSEcCtD
Tramadol—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00123	0.00777	CcSEcCtD
Tramadol—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00122	0.00771	CcSEcCtD
Tramadol—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00119	0.00751	CcSEcCtD
Tramadol—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.00119	0.00751	CcSEcCtD
Tramadol—Gout—Hydrochlorothiazide—nephrolithiasis	0.00118	0.00746	CcSEcCtD
Tramadol—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00116	0.00737	CcSEcCtD
Tramadol—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.00115	0.00727	CcSEcCtD
Tramadol—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00112	0.0071	CcSEcCtD
Tramadol—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00112	0.0071	CcSEcCtD
Tramadol—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00108	0.00685	CcSEcCtD
Tramadol—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.00104	0.00658	CcSEcCtD
Tramadol—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.000994	0.0063	CcSEcCtD
Tramadol—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.000994	0.0063	CcSEcCtD
Tramadol—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.000979	0.0062	CcSEcCtD
Tramadol—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.000922	0.00584	CcSEcCtD
Tramadol—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.000918	0.00581	CcSEcCtD
Tramadol—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.000909	0.00576	CcSEcCtD
Tramadol—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.000909	0.00576	CcSEcCtD
Tramadol—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.000901	0.00571	CcSEcCtD
Tramadol—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.000893	0.00565	CcSEcCtD
Tramadol—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.000884	0.0056	CcSEcCtD
Tramadol—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.000876	0.00555	CcSEcCtD
Tramadol—Injury—Hydrochlorothiazide—nephrolithiasis	0.000869	0.0055	CcSEcCtD
Tramadol—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.000861	0.00545	CcSEcCtD
Tramadol—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.000853	0.00541	CcSEcCtD
Tramadol—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00085	0.00538	CcSEcCtD
Tramadol—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.000846	0.00536	CcSEcCtD
Tramadol—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.000843	0.00534	CcSEcCtD
Tramadol—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.000843	0.00534	CcSEcCtD
Tramadol—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.000839	0.00531	CcSEcCtD
Tramadol—Thirst—Hydrochlorothiazide—nephrolithiasis	0.000839	0.00531	CcSEcCtD
Tramadol—Purpura—Hydrochlorothiazide—nephrolithiasis	0.000828	0.00525	CcSEcCtD
Tramadol—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.000821	0.0052	CcSEcCtD
Tramadol—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.000802	0.00508	CcSEcCtD
Tramadol—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.000798	0.00506	CcSEcCtD
Tramadol—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.000798	0.00506	CcSEcCtD
Tramadol—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.000792	0.00502	CcSEcCtD
Tramadol—Migraine—Hydrochlorothiazide—nephrolithiasis	0.000786	0.00498	CcSEcCtD
Tramadol—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.000786	0.00498	CcSEcCtD
Tramadol—CHRM3—renal system—nephrolithiasis	0.000775	0.0367	CbGeAlD
Tramadol—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.000756	0.00479	CcSEcCtD
Tramadol—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.000751	0.00476	CcSEcCtD
Tramadol—CHRM3—kidney—nephrolithiasis	0.000749	0.0355	CbGeAlD
Tramadol—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.000748	0.00474	CcSEcCtD
Tramadol—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.000737	0.00467	CcSEcCtD
Tramadol—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.000732	0.00464	CcSEcCtD
Tramadol—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.000729	0.00462	CcSEcCtD
Tramadol—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.000729	0.00462	CcSEcCtD
Tramadol—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.000727	0.0046	CcSEcCtD
Tramadol—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.000721	0.00457	CcSEcCtD
Tramadol—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.000719	0.00455	CcSEcCtD
Tramadol—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000719	0.00455	CcSEcCtD
Tramadol—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.000719	0.00455	CcSEcCtD
Tramadol—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.000707	0.00448	CcSEcCtD
Tramadol—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000704	0.00446	CcSEcCtD
Tramadol—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.000704	0.00446	CcSEcCtD
Tramadol—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.000695	0.0044	CcSEcCtD
Tramadol—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00069	0.00437	CcSEcCtD
Tramadol—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00069	0.00437	CcSEcCtD
Tramadol—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.000677	0.00429	CcSEcCtD
Tramadol—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.000672	0.00426	CcSEcCtD
Tramadol—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.000645	0.00409	CcSEcCtD
Tramadol—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.000641	0.00406	CcSEcCtD
Tramadol—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.000637	0.00404	CcSEcCtD
Tramadol—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.000636	0.00403	CcSEcCtD
Tramadol—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00063	0.00399	CcSEcCtD
Tramadol—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.000622	0.00394	CcSEcCtD
Tramadol—CYP2B6—nephron tubule—nephrolithiasis	0.00062	0.0294	CbGeAlD
Tramadol—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.000619	0.00392	CcSEcCtD
Tramadol—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00061	0.00386	CcSEcCtD
Tramadol—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.000607	0.00384	CcSEcCtD
Tramadol—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.000605	0.00383	CcSEcCtD
Tramadol—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.000603	0.00382	CcSEcCtD
Tramadol—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.000598	0.00379	CcSEcCtD
Tramadol—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.000598	0.00379	CcSEcCtD
Tramadol—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00059	0.00374	CcSEcCtD
Tramadol—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.000587	0.00372	CcSEcCtD
Tramadol—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00058	0.00368	CcSEcCtD
Tramadol—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.000577	0.00366	CcSEcCtD
Tramadol—CYP2B6—renal system—nephrolithiasis	0.000564	0.0267	CbGeAlD
Tramadol—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.000562	0.00356	CcSEcCtD
Tramadol—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.000554	0.00351	CcSEcCtD
Tramadol—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.000552	0.0035	CcSEcCtD
Tramadol—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00055	0.00348	CcSEcCtD
Tramadol—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.000548	0.00347	CcSEcCtD
Tramadol—CYP2B6—kidney—nephrolithiasis	0.000545	0.0258	CbGeAlD
Tramadol—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.000544	0.00345	CcSEcCtD
Tramadol—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.000532	0.00337	CcSEcCtD
Tramadol—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.000522	0.00331	CcSEcCtD
Tramadol—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.000515	0.00326	CcSEcCtD
Tramadol—Flushing—Hydrochlorothiazide—nephrolithiasis	0.000513	0.00325	CcSEcCtD
Tramadol—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.000493	0.00313	CcSEcCtD
Tramadol—Erythema—Hydrochlorothiazide—nephrolithiasis	0.000481	0.00305	CcSEcCtD
Tramadol—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.000474	0.003	CcSEcCtD
Tramadol—Tension—Hydrochlorothiazide—nephrolithiasis	0.000472	0.00299	CcSEcCtD
Tramadol—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.000471	0.00298	CcSEcCtD
Tramadol—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.000467	0.00296	CcSEcCtD
Tramadol—Back pain—Hydrochlorothiazide—nephrolithiasis	0.000465	0.00295	CcSEcCtD
Tramadol—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.000462	0.00293	CcSEcCtD
Tramadol—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.000453	0.00287	CcSEcCtD
Tramadol—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00045	0.00285	CcSEcCtD
Tramadol—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.000446	0.00283	CcSEcCtD
Tramadol—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.000444	0.00282	CcSEcCtD
Tramadol—Agitation—Hydrochlorothiazide—nephrolithiasis	0.000442	0.0028	CcSEcCtD
Tramadol—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.000439	0.00278	CcSEcCtD
Tramadol—Malaise—Hydrochlorothiazide—nephrolithiasis	0.000434	0.00275	CcSEcCtD
Tramadol—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.000432	0.00274	CcSEcCtD
Tramadol—Syncope—Hydrochlorothiazide—nephrolithiasis	0.000431	0.00273	CcSEcCtD
Tramadol—CYP3A4—renal system—nephrolithiasis	0.000426	0.0202	CbGeAlD
Tramadol—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000425	0.00269	CcSEcCtD
Tramadol—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.000423	0.00268	CcSEcCtD
Tramadol—Cough—Hydrochlorothiazide—nephrolithiasis	0.00042	0.00266	CcSEcCtD
Tramadol—CYP2D6—renal system—nephrolithiasis	0.000419	0.0198	CbGeAlD
Tramadol—CYP3A4—kidney—nephrolithiasis	0.000412	0.0195	CbGeAlD
Tramadol—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.000409	0.00259	CcSEcCtD
Tramadol—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.000409	0.00259	CcSEcCtD
Tramadol—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.000409	0.00259	CcSEcCtD
Tramadol—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.000408	0.00258	CcSEcCtD
Tramadol—CYP2D6—kidney—nephrolithiasis	0.000405	0.0192	CbGeAlD
Tramadol—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.000404	0.00256	CcSEcCtD
Tramadol—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.0004	0.00254	CcSEcCtD
Tramadol—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.000396	0.00251	CcSEcCtD
Tramadol—HTR2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.000393	0.0382	CbGpPWpGaD
Tramadol—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.000392	0.00249	CcSEcCtD
Tramadol—Shock—Hydrochlorothiazide—nephrolithiasis	0.000386	0.00245	CcSEcCtD
Tramadol—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.000384	0.00243	CcSEcCtD
Tramadol—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000383	0.00243	CcSEcCtD
Tramadol—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.000379	0.0024	CcSEcCtD
Tramadol—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.000374	0.00237	CcSEcCtD
Tramadol—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.000367	0.00232	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000358	0.00226	CcSEcCtD
Tramadol—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000355	0.00225	CcSEcCtD
Tramadol—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.000352	0.00223	CcSEcCtD
Tramadol—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00035	0.00222	CcSEcCtD
Tramadol—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000349	0.00221	CcSEcCtD
Tramadol—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000345	0.00219	CcSEcCtD
Tramadol—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.000344	0.0334	CbGpPWpGaD
Tramadol—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000341	0.00216	CcSEcCtD
Tramadol—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000338	0.00214	CcSEcCtD
Tramadol—Pain—Hydrochlorothiazide—nephrolithiasis	0.000336	0.00213	CcSEcCtD
Tramadol—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000336	0.00213	CcSEcCtD
Tramadol—HTR2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.000331	0.0321	CbGpPWpGaD
Tramadol—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000323	0.00205	CcSEcCtD
Tramadol—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000321	0.00203	CcSEcCtD
Tramadol—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00032	0.0311	CbGpPWpGaD
Tramadol—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000312	0.00197	CcSEcCtD
Tramadol—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00031	0.00197	CcSEcCtD
Tramadol—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00031	0.00197	CcSEcCtD
Tramadol—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000289	0.00183	CcSEcCtD
Tramadol—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000282	0.00178	CcSEcCtD
Tramadol—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000278	0.00176	CcSEcCtD
Tramadol—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000268	0.0017	CcSEcCtD
Tramadol—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.000268	0.0261	CbGpPWpGaD
Tramadol—OPRD1—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000263	0.0256	CbGpPWpGaD
Tramadol—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000259	0.00164	CcSEcCtD
Tramadol—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000249	0.00158	CcSEcCtD
Tramadol—Rash—Hydrochlorothiazide—nephrolithiasis	0.000247	0.00157	CcSEcCtD
Tramadol—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000247	0.00157	CcSEcCtD
Tramadol—Headache—Hydrochlorothiazide—nephrolithiasis	0.000246	0.00156	CcSEcCtD
Tramadol—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000233	0.00148	CcSEcCtD
Tramadol—OPRK1—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000231	0.0224	CbGpPWpGaD
Tramadol—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00023	0.0224	CbGpPWpGaD
Tramadol—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000225	0.0219	CbGpPWpGaD
Tramadol—CHRM3—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000208	0.0202	CbGpPWpGaD
Tramadol—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000206	0.02	CbGpPWpGaD
Tramadol—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000206	0.02	CbGpPWpGaD
Tramadol—OPRM1—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000195	0.019	CbGpPWpGaD
Tramadol—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000156	0.0152	CbGpPWpGaD
Tramadol—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000156	0.0152	CbGpPWpGaD
Tramadol—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000145	0.0141	CbGpPWpGaD
Tramadol—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000145	0.0141	CbGpPWpGaD
Tramadol—HTR2C—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000136	0.0132	CbGpPWpGaD
Tramadol—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000129	0.0126	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000128	0.0125	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000128	0.0125	CbGpPWpGaD
Tramadol—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000121	0.0118	CbGpPWpGaD
Tramadol—CYP2B6—Biological oxidations—SLC26A1—nephrolithiasis	0.000121	0.0117	CbGpPWpGaD
Tramadol—OPRD1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000119	0.0116	CbGpPWpGaD
Tramadol—CHRM3—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000117	0.0114	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000114	0.0111	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000105	0.0102	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000105	0.0102	CbGpPWpGaD
Tramadol—OPRK1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000105	0.0102	CbGpPWpGaD
Tramadol—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000105	0.0102	CbGpPWpGaD
Tramadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000102	0.00994	CbGpPWpGaD
Tramadol—HTR2C—G alpha (q) signalling events—CHRM3—nephrolithiasis	9.82e-05	0.00955	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—RGS14—nephrolithiasis	9e-05	0.00876	CbGpPWpGaD
Tramadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	8.96e-05	0.00871	CbGpPWpGaD
Tramadol—OPRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	8.84e-05	0.00859	CbGpPWpGaD
Tramadol—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	8.78e-05	0.00854	CbGpPWpGaD
Tramadol—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	8.38e-05	0.00815	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—RGS14—nephrolithiasis	8.17e-05	0.00795	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	7.94e-05	0.00772	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	7.94e-05	0.00772	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—RGS14—nephrolithiasis	7.89e-05	0.00768	CbGpPWpGaD
Tramadol—OPRD1—GPCR ligand binding—CHRM3—nephrolithiasis	7.78e-05	0.00757	CbGpPWpGaD
Tramadol—HTR2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	7.59e-05	0.00738	CbGpPWpGaD
Tramadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	7.57e-05	0.00736	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	7.38e-05	0.00718	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	7.38e-05	0.00718	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—RGS14—nephrolithiasis	7.17e-05	0.00697	CbGpPWpGaD
Tramadol—OPRD1—GPCR ligand binding—PTH—nephrolithiasis	7.12e-05	0.00692	CbGpPWpGaD
Tramadol—OPRK1—GPCR ligand binding—CHRM3—nephrolithiasis	6.82e-05	0.00663	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—RGS14—nephrolithiasis	6.67e-05	0.00649	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	6.58e-05	0.0064	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	6.58e-05	0.0064	CbGpPWpGaD
Tramadol—HTR2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	6.5e-05	0.00632	CbGpPWpGaD
Tramadol—OPRK1—GPCR ligand binding—PTH—nephrolithiasis	6.24e-05	0.00607	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—DGKH—nephrolithiasis	6.08e-05	0.00591	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—RGS14—nephrolithiasis	6.06e-05	0.00589	CbGpPWpGaD
Tramadol—OPRM1—GPCR ligand binding—CHRM3—nephrolithiasis	5.77e-05	0.00561	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—RGS14—nephrolithiasis	5.73e-05	0.00557	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—ADCY10—nephrolithiasis	5.68e-05	0.00552	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—DGKH—nephrolithiasis	5.52e-05	0.00537	CbGpPWpGaD
Tramadol—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	5.48e-05	0.00533	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—DGKH—nephrolithiasis	5.33e-05	0.00519	CbGpPWpGaD
Tramadol—OPRM1—GPCR ligand binding—PTH—nephrolithiasis	5.27e-05	0.00513	CbGpPWpGaD
Tramadol—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	5.26e-05	0.00511	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—RGS14—nephrolithiasis	5.2e-05	0.00506	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—ADCY10—nephrolithiasis	4.98e-05	0.00484	CbGpPWpGaD
Tramadol—HTR2C—GPCR ligand binding—CHRM3—nephrolithiasis	4.95e-05	0.00481	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—RGS14—nephrolithiasis	4.93e-05	0.0048	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—DGKH—nephrolithiasis	4.84e-05	0.00471	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—RGS14—nephrolithiasis	4.83e-05	0.0047	CbGpPWpGaD
Tramadol—HTR2C—GPCR ligand binding—PTH—nephrolithiasis	4.53e-05	0.0044	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—DGKH—nephrolithiasis	4.51e-05	0.00438	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—RGS14—nephrolithiasis	4.48e-05	0.00436	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—CHRM3—nephrolithiasis	4.4e-05	0.00428	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—RGS14—nephrolithiasis	4.23e-05	0.00412	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—ADCY10—nephrolithiasis	4.21e-05	0.00409	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—DGKH—nephrolithiasis	4.09e-05	0.00398	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—PTH—nephrolithiasis	4.02e-05	0.00391	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—CHRM3—nephrolithiasis	3.99e-05	0.00388	CbGpPWpGaD
Tramadol—CHRM3—GPCR ligand binding—PTH—nephrolithiasis	3.9e-05	0.00379	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—DGKH—nephrolithiasis	3.87e-05	0.00376	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—CHRM3—nephrolithiasis	3.86e-05	0.00375	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—PTH—nephrolithiasis	3.65e-05	0.00355	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—ADCY10—nephrolithiasis	3.61e-05	0.00352	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—RGS14—nephrolithiasis	3.58e-05	0.00348	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—PTH—nephrolithiasis	3.53e-05	0.00343	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—DGKH—nephrolithiasis	3.51e-05	0.00342	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—CHRM3—nephrolithiasis	3.5e-05	0.0034	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—DGKH—nephrolithiasis	3.33e-05	0.00324	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—DGKH—nephrolithiasis	3.26e-05	0.00317	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.26e-05	0.00317	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	3.26e-05	0.00317	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—PTH—nephrolithiasis	3.2e-05	0.00311	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—GRHPR—nephrolithiasis	3.16e-05	0.00308	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—ADCY10—nephrolithiasis	3.11e-05	0.00303	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—RGS14—nephrolithiasis	3.07e-05	0.00299	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—DGKH—nephrolithiasis	3.03e-05	0.00294	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—PTH—nephrolithiasis	2.98e-05	0.0029	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—CHRM3—nephrolithiasis	2.96e-05	0.00288	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.86e-05	0.00278	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—DGKH—nephrolithiasis	2.86e-05	0.00278	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—AGXT—nephrolithiasis	2.82e-05	0.00274	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—CHRM3—nephrolithiasis	2.8e-05	0.00272	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—GRHPR—nephrolithiasis	2.72e-05	0.00265	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—PTH—nephrolithiasis	2.71e-05	0.00263	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—RGS14—nephrolithiasis	2.65e-05	0.00257	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—PTH—nephrolithiasis	2.56e-05	0.00249	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CHRM3—nephrolithiasis	2.54e-05	0.00247	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—AGXT—nephrolithiasis	2.43e-05	0.00236	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—DGKH—nephrolithiasis	2.42e-05	0.00235	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.42e-05	0.00235	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—SLC26A1—nephrolithiasis	2.4e-05	0.00233	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—APRT—nephrolithiasis	2.4e-05	0.00233	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CHRM3—nephrolithiasis	2.36e-05	0.00229	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—PTH—nephrolithiasis	2.32e-05	0.00226	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—PTH—nephrolithiasis	2.2e-05	0.00214	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—PTH—nephrolithiasis	2.16e-05	0.0021	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.08e-05	0.00202	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—DGKH—nephrolithiasis	2.08e-05	0.00202	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CHRM3—nephrolithiasis	2.07e-05	0.00201	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—SLC26A1—nephrolithiasis	2.06e-05	0.00201	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—APRT—nephrolithiasis	2.06e-05	0.00201	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—PTH—nephrolithiasis	2e-05	0.00195	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—GRHPR—nephrolithiasis	1.89e-05	0.00184	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—PTH—nephrolithiasis	1.89e-05	0.00184	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—ATP6V0A4—nephrolithiasis	1.79e-05	0.00174	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—DGKH—nephrolithiasis	1.79e-05	0.00174	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CHRM3—nephrolithiasis	1.75e-05	0.0017	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—AQP1—nephrolithiasis	1.71e-05	0.00166	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—AGXT—nephrolithiasis	1.69e-05	0.00164	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—PTH—nephrolithiasis	1.6e-05	0.00155	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CHRM3—nephrolithiasis	1.5e-05	0.00146	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—AQP1—nephrolithiasis	1.47e-05	0.00143	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—APRT—nephrolithiasis	1.43e-05	0.00139	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	1.43e-05	0.00139	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—PTH—nephrolithiasis	1.37e-05	0.00134	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—CHRM3—nephrolithiasis	1.33e-05	0.00129	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—GRHPR—nephrolithiasis	1.24e-05	0.0012	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—PTH—nephrolithiasis	1.18e-05	0.00115	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—AGXT—nephrolithiasis	1.1e-05	0.00107	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—SPP1—nephrolithiasis	1.08e-05	0.00105	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—AQP1—nephrolithiasis	1.02e-05	0.000994	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—SPP1—nephrolithiasis	9.5e-06	0.000923	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—APRT—nephrolithiasis	9.38e-06	0.000912	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	9.38e-06	0.000912	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—CHRM3—nephrolithiasis	9.24e-06	0.000899	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—SPP1—nephrolithiasis	8.03e-06	0.00078	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—SPP1—nephrolithiasis	6.89e-06	0.00067	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—AQP1—nephrolithiasis	6.68e-06	0.00065	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—CHRM3—nephrolithiasis	6.04e-06	0.000588	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—SPP1—nephrolithiasis	5.93e-06	0.000577	CbGpPWpGaD
